• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
RAC

RACE ONCOLOGY LTD - News & Media

0.84% ! $1.18
Market Cap $204.1M  !
Healthcare Biotechnology
Add to My Watchlist

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a... Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care.More

Corporate Spotlight

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care.
View the full Corporate Spotlight arrow Created with Sketch.

RAC Accelerates Game-Changing Cancer Drug

Articles & Videos

Race Oncology accelerates gamechanging cancer drug

In this HotCopper Capital Compass interview, Race Oncology (ASX:RAC) chairman Dr Pete Smith discusses the company’s @safe and successful” Phase One clinical trials and the RC220 plus doxorubicin dosing done at the time.Listen to the HotCopper podcast for in-d...

02 Jul 2025 09:48 (AEST)

Race Oncology approved for Phase I trial for chemotherapeutic treatments

Race Oncology Ltd has received approval to go ahead with its Phase I trial to assess R220 and begin enrolling patients

14 Mar 2025 10:10 (AEDT)

Race identifies 39 new molecules with potential to inhibit cancer-associated protein

Race Oncology Ltd has completed a successful drug discovery program started in 2022 at Monash University in Melbourne

21 Nov 2024 11:39 (AEDT)

Race delivers promising results in cancer drug mice research into heart complications

Race Oncology (ASX:RAC) has announced a preclinical breakthrough in heart toxicity side effects caused by the carfilzomib, which had precluded the drug being administered to patients diagnosed with elevated cardiac risk factors.In work performed under contract by Labcorp in the United States, Rac...

13 Jun 2024 11:12 (AEST)

Breaking barriers in cancer treatment: Race Oncology pioneers a new era with bisantrene

Race Oncology (ASX:RAC) has announced positive results in killing cancer cells in combination with the drug bisantrene

14 May 2024 09:56 (AEST)

Race Oncology flags bisantrene "anticancer" properties in animals

Race Oncology (ASX:RAC) presented some major advancements in the potential treatment of Acute Myeloid Leukemia (AML)

06 Mar 2024 11:25 (AEDT)

Dr Daniel Tillett takes the helm as CEO of Race Oncology

Race Oncology (ASX:RAC) has appointed Dr Daniel Tillett as its newest Chief Executive Officer, effective immediately.

22 Nov 2023 10:24 (AEDT)

Race Oncology confirms RC220 peripheral infusion safety in preclinical models

Race Oncology (ASX:RAC) has completed its series of preclinical animal and laboratory studies using its novel bisantrene formulation, RC220.

17 Oct 2023 11:02 (AEDT)

Race Oncology manufactures first cGMP bisantrene batch with Laurus Labs

Race Oncology (ASX:RAC) produces its first batch of bisantrene dihydrochloride under cGMP standards through its partnership with Laurus Labs.

27 Sep 2023 10:57 (AEST)

Race Oncology's (ASX:RAC) bisantrene demonstrates broad anti-cancer activity in latest test results

Race Oncology (ASX:RAC) has announced successful test results of its Bisantrene anti-cancer medication showing broad "anti-cancer activity" in 143 human cancer cell samples.

21 Sep 2023 14:45 (AEST)



Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
$1.18 		Change
-0.010(0.84%) 		Mkt cap ! $204.1M
Open High Low Value Volume
$1.18 $1.19 $1.16 $76.76K 65.43K

Buyers (Bids)

No. Vol. Price($)
4 20389 $1.17
 

Sellers (Offers)

Price($) Vol. No.
$1.20 6324 4
View Market Depth
Last trade - 15.57pm 30/07/2025 (20 minute delay) ?
Last
$1.18 		  Change
-0.010 ( 0.84 %)
Open High Low Volume
$1.18 $1.18 $1.16 9257
Last updated 15.57pm 30/07/2025 ?
RAC (ASX) Chart

Top Stories

Ionic Rare Earths falls -7% as momentum slips on vague production update

Ionic Rare Earths (ASX:IXR) @ a well-known and much-loved rare earths darling on something of a comeback run lately @ has slipped -7%, presumably as the market digests what a vague update released on Wednesday actually means. According to the company, @urgent supply requests from US, European and...
Haranga jumps +7% on Lincoln acquisition Haranga Resources (ASX:HAR) has spiked in intra-day trade after closing the acquisition of the Lincoln Gold Project in California.The Lincoln Project traverses 322 hectares and covers a strike length of the Mother Lode with 5.8km between Sutter Creek and Amador City. It boasts a gold resource of ...
Neurizon inks $1.5M loan against R&D Tax Rebate Neurizon Therapeutics (ASX:NUZ) retreated in intra-day trade on Wednesday after inking a non-dilutive loan agreement for $1.5 million to fund its current and future operations seeking to treat Huntington’s with its flagship drug NUZ-001.The funds in question are secured against it...
HotCopper Trends: Wall of quarterlies dominate; then there's Micro-X & Ionic Let’s check in with what HotCopper users are closely watching at lunchtime. Given that we’re basically on the deadline before companies get a scolding if they don’t report updates, on Wednesday, the ASX announcements list is basically one big wall o...
ASX Market Close: Index rebounds as investors buoyant | July 30, 2025 The ASX200 rebounded today and was in the green heading into the close. Investors were buoyant in response to positive inflation data that increased the odds of an interest rate cut in August.Staples, Real Estate and Discretionary were the strongest performing sectors. Utilities and IT were a dra...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.